David Dai

Stock Analyst at UBS

(0.93)
# 3,906
Out of 5,042 analysts
26
Total ratings
39.13%
Success rate
-11.07%
Average return

Stocks Rated by David Dai

Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $72$97
Current: $94.88
Upside: +2.23%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23$20
Current: $10.78
Upside: +85.53%
Syndax Pharmaceuticals
Jul 15, 2025
Maintains: Buy
Price Target: $37$35
Current: $13.53
Upside: +158.68%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30$26
Current: $11.09
Upside: +134.45%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $19.28
Upside: +55.60%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17$2
Current: $2.25
Upside: -11.11%
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30$24
Current: $7.76
Upside: +209.28%
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $93.39
Upside: +7.08%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27$14
Current: $9.70
Upside: +44.33%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $33.18
Upside: -27.67%
Initiates: Buy
Price Target: $20
Current: $2.99
Upside: +568.90%
Initiates: Buy
Price Target: $69
Current: $24.90
Upside: +177.11%
Initiates: Buy
Price Target: $50
Current: $29.18
Upside: +71.35%
Initiates: Buy
Price Target: $60
Current: $43.67
Upside: +37.39%
Initiates: Outperform
Price Target: $28
Current: $0.89
Upside: +3,046.07%
Initiates: Outperform
Price Target: $40
Current: $57.29
Upside: -30.18%
Initiates: Outperform
Price Target: $40
Current: $1.84
Upside: +2,073.91%
Initiates: Outperform
Price Target: $50
Current: $2.41
Upside: +1,974.69%
Upgrades: Outperform
Price Target: $41$52
Current: $33.19
Upside: +56.67%